Without rapid testing and results, COVID-19 contact tracing will not work. That is the conclusion of a new study published in The Lancet. Even the most efficient contact tracing strategy will not … [Read more...]
Top 4 trends shaping the healthcare industry
By Leora Borgenicht bio Before the healthcare industry can ambitiously transform to offer more accurate and personalized patient care, certain stepping stones must be reached. These four … [Read more...]
Compliance Alert: FDA Warning Letter to Inova Genomics Laboratory
By Danielle Sloane bio and Elaine Naughton bio Despite it being a continual topic of discussion, the Food and Drug Administration ("FDA") enforcement in the realm of laboratory developed tests … [Read more...]
New Broad All-Payor Kickback Law Impacting Laboratories, Commission-based Compensation and more
By Danielle Sloane bio and Chris Climo bio In a recent piece of federal legislation intended to address the opioid crisis across the United States, Congress enacted a new all-payor kickback … [Read more...]
Evidence Building for Use of Liquid Biopsy to Drive Treatment Decisions, Monitor Disease Activity
Emerging evidence shows that liquid biopsy is a viable option for detecting and monitoring genomic mutations to inform treatment decisions and to assess disease activity in real-world clinical … [Read more...]
6 Steps to Data-Driven Transformation
By Nir Kaldero bio We're now well into the Fourth Industrial Revolution. The First Industrial Revolution was about steam and railroads, the Second about electricity, and the Third brought … [Read more...]
Labs Need to Take Elevated Role in Health Care
Labs need to take a more prominent role in the broader health care ecosystem—from being a recognized member of patient care teams to being a leading player in health system financial … [Read more...]
New Test Aids Lung Cancer Risk Assessment, But Survival Benefit of Comprehensive Sequencing Questioned
Lung cancer-related testing is receiving a lot of attention, but recent results appear to show mixed benefits for these emerging tests. There is an urgent need to improve lung cancer risk assessment, … [Read more...]
Cost Avoidance vs Cost Savings: What’s the Difference?
By Jennifer Dawson, MHA, DLM (ASCP) bio As I work to spread awareness within the clinical laboratory community about the Cost of Poor Quality (COPQ) concept and its benefits as a method to … [Read more...]
Noninvasive Gene Expression Test for Melanoma Cuts Costs
The noninvasive pigmented lesion assay (PLA; DermTech) reduces costs compared to the current standard of care for diagnostic workup of pigmented skin lesions suggestive of melanoma, according to a … [Read more...]